FORMA Therapeutics Announces Oncology Collaboration with Novartis
News Jul 30, 2009
FORMA Therapeutics announced that it has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology. Financial terms of the collaboration were not disclosed.
“FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund,” said Steven Tregay, CEO of FORMA. “This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE